| Literature DB >> 32051620 |
Stefania Ciafrè1, Giampiero Ferraguti2, Paola Tirassa3, Angela Iannitelli4, Massimo Ralli5, Antonio Greco5, George N Chaldakov6, Pamela Rosso2, Elena Fico2, Marisa Patrizia Messina7, Valentina Carito2, Luigi Tarani8, Mauro Ceccanti9, Marco Fiore2.
Abstract
The nerve growth factor (NGF) belongs to a family of proteins named neurotrophins, consisting of NGF, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), NT-4/5 and NT-6. NGF regulates a large number of physiological mechanisms that result in neurotrophic, metabotrophic and/or immunotrophic effects. Neurodegenerative diseases, including Alzheimer disease, psychiatric disorders (e.g. depression and schizophrenia) and brain parasitic infection have in common the effect of changing the brain levels of neurotrophins, in particular NGF. The contribution of both NGF and its receptor TrkA in such events and the recent promising results of NGF based therapies are here presented and discussed.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32051620 DOI: 10.1708/3301.32713
Source DB: PubMed Journal: Riv Psichiatr ISSN: 0035-6484 Impact factor: 1.911